Clatacef

Clatacef

cefotaxime

Manufacturer:

T. P. Drug

Distributor:

T. P. Drug
Concise Prescribing Info
Contents
Cefotaxime Na
Indications/Uses
Serious infections caused by susceptible strains of designated microorganisms eg, lower resp tract infections including pneumonia, genitourinary infections including uncomplicated gonorrhea, gynecologic infections including pelvic cellulitis, bacteremia/septicemia, skin & skin structure infections, intra-abdominal infections including peritonitis, bone or joint infections, CNS infections. In combination w/ aminoglycoside in cases of confirmed or suspected gm +ve or -ve sepsis, or in patients w/ other serious infections w/ unidentifiable cause. Reduces incidence of infections in patients undergoing surgical procedures (perioperative prophylaxis); post-op infections during caesarian section.
Dosage/Direction for Use
IM/IV Duration of therapy: Continue treatment for min of 48-72 hr in general. Min of 10 days for infections caused by group A β-hemolytic Strep. Adult & childn weighing ≥50 kg Max: 12 g daily. Adult Gonococcal urethritis/cervicitis 0.5 g IM as single dose. Rectal gonorrhea 1 g IM as single dose in men, 0.5 g IM as single dose in women. Moderate to severe infections 1-2 g every 8 hr. More severe infections needing higher dose of antibiotics eg, septicemia 2 g IV every 6-8 hr. Life-threatening infections 2 g IV every 4 hr up to 12 g daily. Perioperative prophylaxis Recommended dose: Administer single 1 g 30-90 min prior to surgery. Cesarean section 1st dose: Administer 1 g IV as soon as the umbilical cord is clamped. 2nd & 3rd dose: Give 1 g at 6 & 12 hr after 1st dose. Uncomplicated infections 1 g every 12 hr. Childn 1 mth to 12 yr weighing <50 kg 50-180 mg/kg daily in 4-6 divided doses, 1-4 wk 50 mg/kg IV every 8 hr, 0-1 wk 50 mg/kg IV every 12 hr. Renal impairment w/ CrCl 10-50 mL/min Give doses every 12-24 hr, CrCl <10 mL/min Give doses every 24 hr. Adult receiving continuous renal replacement therapy 1 g every 12 hr, continuous venovenous hemofiltration 1-2 g IV every 8-12 hr, continuous venovenous hemodialysis 1-2 g IV every 8 hr, continuous venovenous hemodiafiltration 1-2 g IV every 6-8 hr. Adult receiving intermittent hemodialysis 0.5-2 g supplement after dialysis. Alternatively, 1-2 g IV every 24 hr after dialysis on dialysis days. Continuous ambulatory peritoneal dialysis 0.5-1 g every 24 hr.
Contraindications
Hypersensitivity to cefotaxime or other cephalosphorins.
Special Precautions
Discontinue treatment if skin rash, irritation or edema; allergic reaction occurs. Arrhythmia; pseudomembranous colitis; granulocytopenia & agranulocytosis; perivascular extravasation; superinfection. Increased risk of development of drug-resistant bacteria. Patients w/ type I hypersensitivity reactions to penicillin; history of GI disease particularly colitis. Monitor blood counts for treatments lasting >10 days. Regularly monitor infusion sites to minimize potential for tissue inflammation. May affect ability to drive or operate machinery. Renal impairment. Pregnancy & lactation. Childn. Elderly (monitor renal function).
Adverse Reactions
Colitis, diarrhea; eosinophilia; fever, pruritus, rash; inj site inflammation (IV), pain, induration & tenderness (IM). SJS, TEN.
Drug Interactions
Increased nephrotoxicity w/ aminoglycosides. Induce +ve direct Coombs' test.
MIMS Class
Cephalosporins
ATC Classification
J01DD01 - cefotaxime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Clatacef inj 1 g
Packing/Price
50 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in